Tumor-infiltrating B cells: The ignored players in tumor immunology - PubMed (original) (raw)

Tumor-infiltrating B cells: The ignored players in tumor immunology

Michael Linnebacher et al. Oncoimmunology. 2012.

Abstract

B cells infiltrating into solid tumors are poorly investigated despite their described positive prognostic value. Whether this antitumor potential comes from either the antigen presentation or the antibody production capacity of B cells, or both, is unknown. Our recently published method on tumor-infiltrating B lymphocyte cloning may prove helpful in unraveling the actual relevance of these cells for tumor development and response to therapy.

PubMed Disclaimer

Figures

None

Figure 1. Potential interactions of tumor-infiltrating B cells (TiBcs) with cancer and immune cells. TiBc may either inhibit or promote tumor growth. Tumor-infiltrating plasma cells secrete specific antibodies that favor opsonisation, complement-mediated lysis, or antibody-dependent cellular cytotoxicity. Tumor-suppressing killer B cells have the capacity to directly eliminate tumor cells via lytic proteins (i.e., TNFα, granzyme B). A subset of regulatory B cells exerts tumor-suppressive capacity by secretion of unknown (but most likely proinflammatory and T cell stimulatory) factors. TiBcs take up antigens, migrate to sentinel lymph nodes and present processed antigens to T cells. Activated and expanded antitumoral T cells subsequently infiltrate the tumor. Contrary, a suppressive subset of regulatory B cells may support tumor growth and metastasis by IL-10 and TGFβ production. This favors Th2 and inhibits Th1 immune responses (in particular the secretion of IFNγ). As a consequence, Tregs and other immunosuppressive cell populations (TAM, MDSC) are recruited to the tumor. This generally inhibits proinflammatory anti-tumor T cells.

Similar articles

Cited by

References

    1. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4. doi: 10.1126/science.1129139. - DOI - PubMed
    1. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012;72:1070–80. doi: 10.1158/0008-5472.CAN-11-3218. - DOI - PMC - PubMed
    1. Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, Pilch H, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008;68:5405–13. doi: 10.1158/0008-5472.CAN-07-5206. - DOI - PubMed
    1. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol. 2010;185:4977–82. doi: 10.4049/jimmunol.1001323. - DOI - PubMed
    1. Coronella-Wood JA, Hersh EM. Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother. 2003;52:715–38. doi: 10.1007/s00262-003-0409-4. - DOI - PMC - PubMed

LinkOut - more resources